Alicia Russo

IAM Research

The Patent 1000 focuses exclusively on patent practice and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.

Recommended - Individuals: transactions

With its New York lawyers in the driving seat, Venable has been on a fine run of form in patent litigation of late. Much credit for this is owed to Dominick Conde, William Solander, Ha Kung Wong and Scott Reed, who form the nucleus of one of the best pharmaceutical and biotechnology groups around – as their caseload bears out. IP division co-chair Conde represents Allergan and is opposing a challenge to a patent relating to its Botox product; Solander has enjoyed great success in multiple post-grant reviews on behalf of Grünenthal and Abiogen Pharma to invalidate patents owned by Antecip Bioventures II relating to treatments for complex regional pain syndrome; Wong has been contributing in vital ways on the litigation front – for example, supporting Conde in his Allergan work – while also maintaining a strong focus on licensing and acquisitions; and Reed continues to bring leadership as co-chair of the IP litigation life sciences group. Props also go to Michael Sandonato, Frank Gasparo and Christopher Borello, who take centre stage when high-technology disputes need to be fought and won. Sandonato has been busy for long-time client Canon and is defending it in two NPE suits; Philips is his other main representation – he is serving as lead counsel for the company in a set of consolidated cases involving patents on graphical user interface, streaming and content protection technologies, many of which have been resolved favourably, but with one trial coming up. He co-chairs the IP litigation division with Gasparo, an adept, business-focused trial lawyer who makes all the right plays in district courts, the ITC, the PTAB and the Federal Circuit. Not easily pigeonholed, Borello performs adroitly in pharmaceutical and non-life sciences cases; capitalising on his patent counselling and portfolio development know-how, he addresses litigation issues holistically. An expert on biologics and small molecule pharmaceuticals with research experience on her CV, Alicia Russo is a highly proficient deal lawyer. She does great and many things for Gilead Sciences, and recently oversaw its $21 billion acquisition of Immunomedics.

Get unlimited access to all IAM content